A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
for Advanced Urothelial Carcinoma
12 locations incl. San Francisco
Sponsor: Flare Therapeutics Inc.
Sex: All·Age: 18+
Code: NCT05929235·Phase 1·Recruiting